The tumour suppressor PTEN (phosphatase and tensin homologue deleted on chromosome 10) plays essential roles in regulating signalling pathways involved in cell growth and apoptosis, and is inactivated in a wide variety of tumours. The role of PTEN as a tumour suppressor has been firmly established; however, the mechanism(s) by which its function and activity are regulated remains elusive. Here, we summarize recent progress in research directed towards trying to understand the molecular basis of regulatory mechanisms for PTEN. We also describe our novel finding that a tumour suppressor candidate protein binds to extreme C-terminal region of PTEN and regulates PTEN protein turnover.
Introduction
PTEN (phosphatase and tensin homologue deleted on chromosome 10)/MMAC1 (mutated in multiple advanced cancers 1)/TEP1 (transforming growth factor β-regulated and epithelial cell-enriched phosphatase 1) was first identified as a candidate tumour suppressor gene [1] [2] [3] . Hundreds of PTEN mutations have been found in a wide variety of human tumours, and germline mutations in the PTEN gene appear to be associated with cancer-prone familial diseases, such as Cowden syndrome and related diseases, supporting the conclusion that PTEN functions as a tumour suppressor [4] [5] [6] [7] . The human PTEN gene encodes a protein of approx. 50 kDa, consisting of an N-terminal phosphatase domain, a C2 domain and an extended C-terminal region (C-tail) ( Figure 1 ). All known vertebrate PTEN proteins are highly similar in their amino acid sequences, with identity of 81-100%, suggesting that their physiological functions and regulatory mechanisms are highly conserved.
The PTEN tumour suppressor antagonizes the actions of PI3K (phosphoinositide 3-kinase) by dephosphorylating the second messenger PtdIns(3,4,5)P 3 , which is produced by PI3K in response to a variety of stimuli. PTEN plays an indispensable role in the regulation of PI3K/PtdIns(3,4,5)P 3 -mediated signals, and loss-of-function mutations in the PTEN gene have a severe impact on cellular signal transduction [4] [5] [6] [7] . In addition to research aimed towards elucidating the fundamental role(s) of PTEN as a tumour suppressor, recent studies have focused on the regulatory mechanisms for PTEN function and activity. A number of Key words: phosphatase, phosphoinositide, post-translational modification, protein turnover, tumour suppressor. Abbreviations used: GFP, green fluorescent protein; MAGI, membrane-associated guanylate kinase with inverted orientation; PICT, protein interacting with the C-tail; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homologue deleted on chromosome 10; siRNA, short interfering RNA. 1 To whom correspondence should be addressed (e-mail tmaehama@rinshoken.or.jp).
studies have revealed that the activity of PTEN is regulated by (i) recruitment of PTEN protein to correct subcellular location(s), (ii) post-translational modification, such as phosphorylation, and (iii) alterations in PTEN protein levels ( Figure 2) . One of the greatest advances in these areas was the finding of phosphorylation in the C-tail region [8, 9] , shedding light on the mechanism of regulation of PTEN activity at the post-translational level. The C-tail appears to be involved in all regulatory mechanisms described above, and its phosphorylation functions as a crucial step in the C-tail-mediated regulation of PTEN.
This paper highlights recent advances in our understanding of the regulatory mechanisms behind PTEN function and activity in cells, particularly C-tail-governed regulatory mechanisms. We also discuss our novel finding on the regulation of PTEN protein turnover via interaction with a tumour suppressor candidate protein (F. Okahara, Y. Kanaho and T. Maehama, unpublished work).
Regulatory role of the C-tail in PTEN protein stability and activity
All vertebrate PTENs possess a C-tail that is rich in serine/ threonine residues ( Figure 1 ). It is now widely accepted that human PTEN is phosphorylated on the C-tail when expressed in mammalian cells. To date, five serine/threonine residues (Ser 370 , Ser 380 , Thr 382 , Thr 383 and Ser 385 ) in the C-tail have been found to be phosphorylated both in vivo and in vitro (Figure 1 ) [8, 9, 11, 12] . Ser 370 , Thr 383 and Ser 385 meet the criteria of a minimal consensus sequence (Ser/Thr-Xaa-Xaaacidic) for phosphorylation by the protein kinase CK2 (Figure 1) , and these residues are substantially phosphorylated by CK2 in vitro [9, 12] . Furthermore, CK2 inhibitors reduced the levels of phosphorylation of PTEN in cells [12] , suggesting that CK2 phosphorylates these residues directly in cells. Although the kinase(s) responsible for phosphorylation of Ser 380 and Thr 382 remains unknown, it should be noted that these residues would also meet the criteria for CK2 target sequences when Thr 383 and Ser 385 are phosphorylated (Ser-Asp-Thr-pThr and Thr-Thr-Asp-pSer respectively) ( Figure 1 ). It is conceivable that CK2 sequentially phosphorylates all five of these residues. A recent study has shown that phosphorylation on the C-tail is induced in a PtdIns(3,4,5)P 3 /PI3K-dependent manner [11] . However, it still remains unclear how PtdIns(3,4,5)P 3 /PI3K conveys the signal towards CK2 and/or other kinase(s) to phosphorylate the C-tail, and the phosphatase(s) responsible for dephosphorylating the C-tail is yet to be identified.
A role for the C-tail in PTEN function/activity was first described in a study on the characterization of tumourassociated C-tail mutants [13] . Almost all C-tail mutants, including both deletions and missense mutants, are extremely unstable in mammalian cells, exhibiting quite short protein half-lives [13] [14] [15] [16] . Truncation of 18 amino acids or more from the C-terminus appears to be sufficient to produce an unstable mutant protein. In addition, a single amino acid substitution at Leu 345 (L345Q) or Thr 348 (T348I) also results in rapid degradation of the mutant proteins in cells [13] . Collectively, these observations indicate a regulatory role for the C-tail in stabilizing and maintaining PTEN protein in cells. It is noteworthy that deletions and missense mutations (including L345Q and T348I) in the C-tail comprise approx. 20% of all known tumour-associated PTEN mutations [5, 17] . The instability of the C-tail mutants may explain the loss-offunction mechanism for these tumour-associated mutations. These mutations cause the mutant PTEN proteins to be quite unstable in cells, followed by their rapid disappearance (lossof-function).
In addition to these tumour-associated C-tail mutations, amino acid substitutions at the phosphorylation sites also have marked effects on protein stability. Single or multiple substitution of the phosphorylation sites with alanine, which results in phosphorylation-resistant mutants, significantly decreases the stability of PTEN protein in cells [8, 9, 11, 12, 18] . In contrast, a phosphorylation-mimicking mutant, in which the phosphorylation sites are substituted with glutamic acid or aspartic acid, displays no alteration in stability [8, 9, 12, 18] . Phosphorylation on these serine/threonine residues, presumably by CK2, appears to play an important role in stabilizing PTEN protein in cells. The degradation of PTEN proceeds in both a proteasome-and a caspase-3-dependent manner [9, 18, 19] . Caspase-3 initially cleaves PTEN at several target sites (Asp/Asn-Xaa-Xaa-Asp) in the C-tail (Figure 1 ) and converts proteins into truncated forms that are predisposed to being degraded in a proteasome-dependent manner.
Recent research has also revealed that phosphorylation of the C-tail by CK2 reduces the phosphatase activity of PTEN in vitro [12] . However, C-tail phosphorylation also inhibits the recruitment of PTEN to the plasma membrane, which is required in order for PTEN to exhibit its function (see Figure 2 ; discussed in detail below). Thus C-tail phosphorylation appears to stabilize PTEN protein, but decreases PTEN activity. The functional consequences of the shuttling of the status of PTEN between the phosphorylated form (stable but inactive) and the unphosphorylated form (active but unstable) remain elusive.
Regulation of PTEN protein turnover by a protein-protein interaction
Phosphorylation of the C-tail of PTEN has multiple functions, regulating several aspects of PTEN activity. In addition, we recently identified a protein that binds to the C-tail and regulates PTEN protein turnover (Figure 2) . This protein, which we referred to as PICT-1 (protein interacting with the C-tail-1), was isolated from a human brain library by yeast two-hybrid screening in which the PTEN C-tail region was used as bait (F. Okahara, Y. Kanaho and T. Maehama, unpublished work). Since the PTEN C-tail is apparently involved in PTEN protein turnover, we first examined whether PICT-1 participates in the regulation of protein turnover. For this purpose, we inhibited the protein expression of PICT-1 by RNA interference methods using a specific siRNA (short interfering RNA) against PICT-1. Treatment of human breast carcinoma MCF7 cells with the PICT-1-directed siRNA, PIC318, significantly reduced protein levels of endogenous PTEN without affecting the levels of PTEN transcript, while siRNA against GFP (green fluorescent protein) affected neither protein levels nor transcript levels of PTEN (Figure 3) . Furthermore, overexpression of PICT-1 in human embryonic kidney 293 cells extended the half-life of ectopically expressed PTEN protein [10] . These results raise the possibility that binding of the PTEN C-tail to PICT-1 is another key determinant for stabilizing and maintaining PTEN protein in cells. It is still under investigation whether PICT-1 affects the phosphorylation of PTEN and whether C-tail phosphorylation affects the binding affinity of PTEN for PICT-1. It is noteworthy that the gene encoding PICT-1 is located at 19q13, which is suspected to be a region responsible for human gliomas, neuroblastomas and ovarian carcinomas. In agreement with previous genetic evidence, we observed aberrant PICT-1 mRNA expression in human neuroblastoma specimens with significant frequency (T. Maehama, K. Itoh, F. Okahara and Y. Kanaho, unpublished work). These results suggest that PICT-1 has a suppressive function in these human carcinomas. It is possible that impairment in the PICT-1 gene causes a decrease in PTEN protein levels due to rapid turnover, leading to the activation of PI3K/ PtdIns(3,4,5)P 3 -mediated signals. This is under investigation in our laboratory.
Recruitment of PTEN protein to the plasma membrane
It is widely accepted that the physiological functions of signalling molecules are tightly regulated by their recruitment to specified subcellular loci via intrinsic localization signals and/or associations with specific binding partners. Since PtdIns(3,4,5)P 3 , which is the substrate for PTEN, is a component of the membrane lipid bilayer and is limited to membranes, PTEN must locate at the membranes to function as a PtdIns(3,4,5)P 3 phosphatase. Both the phosphatase domain and the C2 domain of PTEN have significant membrane-binding potential (Figure 2) , and bacterially expressed PTEN binds strongly to phospholipid vesicles in vitro without significant specificity for particular phospholipid species [20, 21] . Tumour-associated mutations in the critical binding region of the C2 domain impair the ability of this domain both to bind to phospholipid vesicles and to inhibit cell proliferation, although the PtdIns(3,4,5)P 3 phosphatase activity of these mutants remains intact [20, 22] . In addition to the intrinsic membrane-binding potential of PTEN, several PDZ domain-containing proteins are known to interact with PTEN and may participate in the recruitment of PTEN to the plasma membrane (Figure 2 ). The PDZ domain-containing proteins S-SCAM (synaptic scaffolding molecule)/MAGI-2 (membrane-associated guanylate kinase with inverted orientation-2), MAGI-3, hDlg, hMAST205 (microtubule-associated serine/threonine kinase, 205 kDa) and MUPP1 (multi-PDZ-domain protein 1) bind to the typical PDZ-binding motif (class I motif; Xaa-Ser/Thr-Xaahydrophobic) at the extreme C-terminus of PTEN [14, 19, [22] [23] [24] [25] . S-SCAM/MAGI-2 and MAGI-3 localize to tight junction and potentially recruit PTEN to this compartment [14, 24] , indicating the involvement of these proteins in the membrane localization of PTEN.
All of these data indicate that PTEN has membranebinding potential and that the binding of PTEN to the plasma membrane is an essential step for exhibiting its biological function. However, PTEN is localized mainly in the cytoplasm or nucleus when expressed in many types of mammalian cells. What overcomes the intrinsic membranebinding ability of PTEN to sequester PTEN from the plasma membranes? One of the most plausible explanations has been provided by studies on PTEN C-tail phosphorylation. Phosphorylation on the C-tail greatly impairs the ability of PTEN to bind to both lipid membranes and PDZ domaincontaining proteins [19, 21, 23, 25, 26] . The phosphorylation may prevent the recruitment of PTEN to the plasma membrane; however, once PTEN is dephosphorylated, the membrane-binding ability of phosphatase domain and C2 domain drive PTEN to translocate to the plasma membrane ( Figure 2) . It is noteworthy that, in differentiated HL60 cells (neutrophil-like) and in Dictyostelium amoebae, PTEN is recruited to trailing-edge membranes in response to chemotactic stimuli [27] [28] [29] . Spatial reorganization of the PTEN target(s) and/or a fundamental change in the characteristics of PTEN protein itself, such as an alteration in the phosphorylation status, appear to be associated with the specific stimulus. Unfortunately, the enzyme(s) responsible for dephosphorylating for PTEN remains unknown. Further studies will be required in order understand the molecular basis for the mechanism of localization for PTEN.
Conclusion
The tumour suppressor PTEN has diverse biological activities, reflecting the multiple functions of its substrate, PtdIns(3,4,5)P 3 . Regulation of PTEN activity may be crucial to govern PI3K/PtdIns(3,4,5)P 3 -mediated cellular responses, such as proliferation and apoptosis. We have mainly described the post-translational regulation of PTEN function and activity in this review. Recent research has indicated that there may be additional regulatory mechanisms for PTEN {e.g. transactivation of the PTEN gene [30] [31] [32] and direct activation of the phosphatase activity of PTEN by PtdIns(4,5)P 2 [33, 34] } that we have not included in this review due to space limitations. Thus the mechanisms of regulation of PTEN appear to be quite complex, and these regulatory processes are likely to affect each other. Further studies will be required in order to gain a more complete understanding of the molecular basis of the mechanisms of regulation of PTEN.
